Phaseline

Targets › ZNT2

ZNT2 (Proton-coupled zinc antiporter SLC30A2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.

[Isoform 1]: Electroneutral proton-coupled antiporter concentrating zinc ions into a variety of intracellular organelles including endosomes, zymogen granules and mitochondria. Thereby, plays a crucial role in cellular zinc homeostasis to confer upon cells protection against its potential cytotoxicity. (UniProt, Q9BRI3)

Open in Phaseline: the race on ZNT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Anhui Provincial HospitalOral elemental zinc supplementation
Zinc supplementation (cofactor for immune cell function)
ZNT1, ZNT2Phase 2Hepatocellular CarcinomaAug 2027

Conditions

Hepatocellular Carcinoma (1)

Modalities

small molecule (1)

Companies

Anhui Provincial Hospital (1)

Related targets

ZNT1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.